Clinical trial
A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT05366166 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 2, 2022
- Completion date
- November 21, 2030
- Enrollment
- 45 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.